Nurix Therapeutics (NRIX) Q3 FY2026 earnings: revenue $673 million, up 8426.3% on the year
Nurix Therapeutics, Inc. (NRIX) reported revenue of $673 million for Q3 FY2026, the quarter ended 31 August 2026, up 8426.3% on the same quarter a year earlier. Net income was $550 million, and diluted earnings per share $4.73. The figures are the company's own, from the 10-Q it filed with the SEC on 13 October 2026.
Revenue$673 millionup 8426.3%
Net income$550 million
Diluted EPS$4.73
QuarterQ3 FY2026ended 31 August 2026
The quarter, against the one before and a year earlier
| Line | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | Change on the year |
|---|---|---|---|---|
| Revenue | 673 | 9.0 | 7.9 | +8426.3% |
| Research and development | 79.3 | 87.7 | 86.1 | -8.0% |
| Operating income | 559 | -94.2 | -91.4 | n/a |
| Operating margin | 83.1% | -1041.7% | -1157.7% | |
| Pre-tax income | 563 | -89.8 | -86.4 | n/a |
| Income tax | 13.6 | -0.3 | 0.0 | n/a |
| Effective tax rate | 2.4% | n/a | n/a | |
| Net income | 550 | -89.5 | -86.4 | n/a |
| Net margin | 81.7% | -990.1% | -1094.8% | |
| Diluted EPS | $4.73 | -$0.81 | -$1.03 | n/a |
$ million except per share.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow and capital returned
| Line | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | Change on the year |
|---|---|---|---|---|
| Operating cash flow | 616 | -96.6 | -57.4 | n/a |
| Capital expenditure | 1.4 | 1.9 | 2.7 | -48.7% |
| Free cash flow | 614 | -98.5 | -60.1 | n/a |
| Free cash flow margin | 91.3% | -1089.3% | -761.3% | |
| Cash from investing | 31.6 | 93.0 | 50.5 | -37.4% |
| Cash from financing | 5.2 | 0.1 | 1.2 | +346.7% |
| Depreciation and amortisation | 2.1 | 2.3 | 2.0 | +5.5% |
| Share-based compensation | 10.8 | 11.4 | 9.8 | +10.3% |
| Dividend per share | $0.00 | $0.00 | $0.00 | n/a |
| Diluted shares, weighted | 116m | 111m | 84m | +38.0% |
| Shares outstanding at period end | 109m | 104m | 77m | +42.1% |
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet at quarter end
| Line | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | Change on the year |
|---|---|---|---|---|
| Shareholders' equity | 968 | 403 | 372 | +160.1% |
| Debt | 0.0 | 0.0 | 0.0 | n/a |
| Operating lease liabilities | 62.1 | 54.9 | 52.7 | +17.8% |
| Other liabilities | 165 | 78.0 | 97.5 | +69.1% |
| Total liabilities and equity | 1,195 | 536 | 522 | +128.8% |
| Fixed assets | 19.4 | 20.0 | 20.5 | -5.3% |
| Securities held for sale or to maturity | 782 | 423 | n/a | n/a |
| Cash and equivalents | 720 | 67.7 | 78.4 | +818.2% |
| Receivables | 20.0 | n/a | n/a | n/a |
| Other assets | n/a | 25.3 | 424 | n/a |
| Total assets | 1,195 | 536 | 522 | +128.8% |
Questions
What was Nurix Therapeutics' revenue in Q3 FY2026?
Nurix Therapeutics (NRIX) reported revenue of $673 million for Q3 FY2026, the quarter ended 31 August 2026, up 8426.3% on the same quarter a year earlier.
How much did Nurix Therapeutics earn in Q3 FY2026?
Net income for Q3 FY2026 was $550 million, and diluted earnings per share $4.73.
When did Nurix Therapeutics report Q3 FY2026 results?
Nurix Therapeutics filed its 10-Q for the quarter ended 31 August 2026 with the SEC on 13 October 2026.
Quarterly results, the last 20 quarters
| Q4 FY2021 * | Q1 FY2022 | Q2 FY2022 | Q3 FY2022 | Q4 FY2022 * | Q1 FY2023 | Q2 FY2023 | Q3 FY2023 | Q4 FY2023 * | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.4 | 9.6 | 11.4 | 10.8 | 6.8 | 12.7 | 30.7 | 18.5 | 15.2 | 16.6 | 12.1 | 12.6 | 13.3 | 18.5 | 44.1 | 7.9 | 13.6 | 6.3 | 9.0 | 673 |
| R&D | 36.5 | 43.1 | 47.5 | 47.8 | 46.1 | 45.8 | 45.8 | 47.9 | 49.7 | 50.0 | 48.9 | 55.5 | 67.2 | 69.7 | 78.1 | 86.1 | 83.0 | 84.1 | 87.7 | 79.3 |
| Operating income | -38.0 | -42.7 | -45.7 | -46.7 | -48.7 | -43.0 | -26.8 | -40.0 | -45.3 | -45.2 | -48.5 | -54.6 | -64.7 | -62.9 | -48.3 | -91.4 | -83.1 | -92.5 | -94.2 | 559 |
| Operating margin | -513% | -444% | -400% | -433% | -718% | -339% | -87% | -217% | -299% | -273% | -401% | -434% | -487% | -341% | -110% | -1158% | -612% | -1479% | -1042% | 83% |
| Pre-tax income | -37.7 | -42.5 | -45.4 | -45.7 | -46.7 | -40.7 | -24.3 | -37.0 | -42.0 | -41.4 | -44.5 | -48.9 | -58.5 | -56.4 | -42.7 | -86.4 | -78.2 | n/a | -89.8 | 563 |
| Tax rate | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2% |
| Net income | -37.7 | -42.5 | -45.4 | -45.7 | -46.7 | -40.7 | -24.3 | -37.0 | -42.0 | -41.5 | -44.5 | -49.0 | -58.5 | -56.4 | -43.5 | -86.4 | -78.2 | -87.2 | -89.5 | 550 |
| Net margin | -510% | -442% | -397% | -424% | -689% | -321% | -79% | -200% | -277% | -250% | -368% | -389% | -441% | -305% | -99% | -1095% | -576% | -1394% | -990% | 82% |
| Diluted EPS | -$0.85 | -$0.95 | -$1.01 | -$0.90 | -$0.87 | -$0.75 | -$0.45 | -$0.68 | -$0.77 | -$0.76 | -$0.71 | -$0.67 | -$0.75 | -$0.67 | -$0.52 | -$1.03 | -$0.82 | -$0.79 | -$0.81 | $4.73 |
| Operating cash flow | -30.9 | -42.6 | -32.9 | -46.3 | -38.0 | -48.5 | -18.5 | -41.1 | 26.7 | -42.0 | -39.7 | -42.2 | -48.8 | -61.1 | -63.2 | -57.4 | -67.8 | -71.9 | -96.6 | 616 |
| Capital expenditure | 0.9 | 3.5 | 2.8 | 3.4 | 2.6 | 2.3 | 1.1 | 2.5 | 2.6 | 2.9 | 1.9 | 2.3 | 2.1 | 3.5 | 2.7 | 2.7 | 5.1 | 1.0 | 1.9 | 1.4 |
| Free cash flow | -31.8 | -46.1 | -35.7 | -49.7 | -40.5 | -50.7 | -19.5 | -43.6 | 24.1 | -44.8 | -41.6 | -44.5 | -50.9 | -64.6 | -65.8 | -60.1 | -73.0 | -73.0 | -98.5 | 614 |
| Shares outstanding | 45m | 45m | 45m | 47m | 47m | 47m | 48m | 49m | 49m | 49m | 64m | 67m | 76m | 76m | 76m | 77m | 102m | 103m | 104m | 109m |
| Filing | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.10-Q for the period ended 31 August 2026, filed 13 October 2026: the filing.